Literature DB >> 9713398

A different look at corticosteroids.

R J Zoorob1, D Cender.   

Abstract

Systemic corticosteroids have been used in the treatment of numerous medical conditions for approximately 50 years. Short-acting products such as hydrocortisone are the least potent. Prednisone and methylprednisolone, which are intermediate-acting products, are four to five times more potent than hydrocortisone. Dexamethasone is a long-acting, systemic corticosteroid; its potency is about 25 times greater than the short-acting products. Corticosteroids reduce the need for hospitalization in patients with croup and decrease morbidity and the incidence of respiratory failure in the treatment of patients with AIDS who have Pneumocystis carinii pneumonia. Other often overlooked indications for corticosteroids are the treatment of hyperthyroid states, including thyroid storm, subacute thyroiditis and ophthalmopathy of Graves' disease. Systemic steroids can be used as adjuvant analgesics in the treatment of neuropathic and cancer-related pain. They may also decrease mortality in patients with severe alcoholic hepatitis and concomitant encephalopathy. Corticosteroids can reduce complications in patients with meningitis caused by Haemophilus influenzae or Mycobacterium tuberculosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9713398

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  34 in total

Review 1.  A Review of the Role of Intravitreal Corticosteroids as an Adjuvant to Antibiotics in Infectious Endophthalmitis.

Authors:  Dawn Ching Wen Ho; Aniruddha Agarwal; Cecilia S Lee; Jay Chhablani; Vishali Gupta; Manoj Khatri; Jayabalan Nirmal; Carlos Pavesio; Rupesh Agrawal
Journal:  Ocul Immunol Inflamm       Date:  2016-11-16       Impact factor: 3.070

2.  Systemic glucocorticoid use and early-onset basal cell carcinoma.

Authors:  Jose Ramon Troche; Leah M Ferrucci; Brenda Cartmel; David J Leffell; Allen E Bale; Susan T Mayne
Journal:  Ann Epidemiol       Date:  2014-05-22       Impact factor: 3.797

Review 3.  Immediate and Delayed Hypersensitivity Reactions to Corticosteroids: Evaluation and Management.

Authors:  Iris M Otani; Aleena Banerji
Journal:  Curr Allergy Asthma Rep       Date:  2016-03       Impact factor: 4.806

4.  Synthesis and Characterization of Poly(2-hydroxyethylmethacrylate) Contact Lenses Containing Chitosan Nanoparticles as an Ocular Delivery System for Dexamethasone Sodium Phosphate.

Authors:  Gautam Behl; Javed Iqbal; Niall J O'Reilly; Peter McLoughlin; Laurence Fitzhenry
Journal:  Pharm Res       Date:  2016-03-10       Impact factor: 4.200

5.  Anti-Atherosclerotic Potential of Aqueous Extract of Cinnamomum Zeylanicum Bark against Glucocorticoid Induced Atherosclerosis in Wistar Rats.

Authors:  Im Nagendra Nayak; Rajasekhar Chinta; Raghu Jetti
Journal:  J Clin Diagn Res       Date:  2017-05-01

6.  First High-Resolution Crystal Structures of the Glucocorticoid Receptor Ligand-Binding Domain-Peroxisome Proliferator-Activated γ Coactivator 1-α Complex with Endogenous and Synthetic Glucocorticoids.

Authors:  Xu Liu; Yashuo Wang; Eric A Ortlund
Journal:  Mol Pharmacol       Date:  2019-08-07       Impact factor: 4.436

7.  Genetic risk factors for decreased bone mineral accretion in children with asthma receiving multiple oral corticosteroid bursts.

Authors:  Heung-Woo Park; Bing Ge; Szeman Tse; Elin Grundberg; Tomi Pastinen; H William Kelly; Kelan G Tantisira
Journal:  J Allergy Clin Immunol       Date:  2015-05-27       Impact factor: 10.793

8.  Effect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravir.

Authors:  Ivy H Song; Julie Borland; Shuguang Chen; Paul Savina; Amanda F Peppercorn; Stephen Piscitelli
Journal:  Antimicrob Agents Chemother       Date:  2013-07-01       Impact factor: 5.191

9.  Glucocorticoid use and complications following immune checkpoint inhibitor use in melanoma.

Authors:  Kapil Agarwal; Nadia Yousaf; Daniel Morganstein
Journal:  Clin Med (Lond)       Date:  2020-03       Impact factor: 2.659

10.  Glucocorticoid therapy and risk of bladder cancer.

Authors:  K Dietrich; A Schned; J Fortuny; J Heaney; C Marsit; K T Kelsey; M R Karagas
Journal:  Br J Cancer       Date:  2009-09-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.